Care Institute and Harvard Medical School. Principal Investigator of the FDA Mini-Sentinel Project and a member of OMOP Executive Board
 
  10:50 AM Andrew Bate, Ph.D., Senior Director, Analytics Team Lead, Epidemiology, Worldwide Safety Strategy (formerly with the WHO Collaborating Centre for International Drug Monitoring, Uppsala Monitoring Centre)
 
  11:10 AM Dan O’Connor, Ph.D., Greenwall Foundation Postdoctoral Fellow in Bioethics and the History of Medicine, Berman Institute of Bioethics and the Institute for the History of Medicine, Johns Hopkins University, Baltimore, MD
 
  11:20 AM Panel Questions
 
11:45 AM Break
 
12:00 PM Panel C—Patient and Public Interest Group Perspective Sydney Wolfe, M.D., Director of the Health Research Group, Public Citizen’s Health Marc Boutin, J.D., Executive Vice President and Chief Operating Officer, The National Health Council.
 
12:30 PM Lunch
 
1:15 PM FDA Representatives Joshua Sharfstein, M.D., Principal Deputy Commissioner, FDA Dr. Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA
 
2:30 PM Adjourn Open Session


The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement